search

Active clinical trials for "Hypertension"

Results 3171-3180 of 5863

To Demonstrate the Relative Bioavailability Study of Ramipril 10 mg Capsules Under Non-Fasting Conditions...

Hypertension

To demonstrate the relative bioavailability study of Ramipril 10 mg capsules under non-fasting conditions.

Completed3 enrollment criteria

Irbesartan and Amlodipine Combination in Controlling Blood Pressure

Hypertension

The primary objective is to compare the extent of reduction of mean Seated Diastolic Blood Pressure (SeDBP) at the end of 8 weeks between each Fixed Dose Combination (FDC), its individual constituents administered as monotherapy and placebo. The secondary objectives are: to compare the reduction of mean Seated Systolic Blood Pressure (SeSBP) at the end of 8 weeks from baseline between each FDC, its individual constituents administered as monotherapy and placebo. to compare the reduction of mean SeDBP and SeSBP at 4 weeks from baseline between each FDC, its individual constituents administered as monotherapy and placebo.

Completed31 enrollment criteria

IV Iron Replacement for Iron Deficiency in Idiopathic Pulmonary Arterial Hypertension (IPAH) Patients...

Pulmonary Arterial HypertensionIron Deficiency

This study will establish whether intravenous iron replacement has clinical benefit in idiopathic pulmonary arterial hypertension. A 24-week double-blind, randomised, placebo-controlled, crossover study will investigate whether a single dose of 1g of Ferinject® or CosmoFer improves cardiopulmonary haemodynamics, exercise capacity and quality of life and is well-tolerated. IV iron formulation used in Europe - Ferinject IV iron formulation used in China - CosmoFer

Completed35 enrollment criteria

Treatment of High Blood Pressure Using Olmesartan With Hydrochlorothiazide Compared to an ACE Inhibitor...

Hypertension

A comparison of 2 different combinations of high blood pressure medications to treat hypertension

Completed5 enrollment criteria

Combination of Telmisartan 40 mg Plus Hydrochlorothiazide (HCTZ) 12.5 mg vs. Telmisartan 40 mg Alone...

Hypertension

The objective of this trial is to demonstrate that the fixed dose combination of telmisartan 40 mg and HCTZ 12.5 mg is superior to the monocomponent of telmisartan (Micardis, Gliosartan, Kinzal, Kinzalmono, Predxal, Pritor, Samertan, Telmisartan) 40 mg in patients with essential hypertension who fail to respond adequately to telmisartan monotherapy.

Completed7 enrollment criteria

ALLOGRAFT, A Study to Evaluate the Renal Protective Effects of Losartan (0954-222)(COMPLETED)

High Blood Pressure

To demonstrate that losartan (+ conventional therapy) compared to placebo (+ conventional therapy) will reduce the number of RT patients who experience histological lesions of chronic allograft nephropathy

Completed17 enrollment criteria

A 12week, Randomized, Evaluator-Masked, Parallel Group Comparing Evening Dosing Of Xalacom Vs Cosopt...

GlaucomaOpen Angle1 more

To demonstrate the statistical non inferiority of the combination of latanoprost and timolol given in the evening time once a day vs the combination of dorzamalide and timolol twice a day based on intraocular pressure measurements at 8 AM, 12 noon & 4 PM during a 12 week treatment.

Completed3 enrollment criteria

IDEAL Study: Identification of the Determinants of the Efficacy of Arterial Blood Pressure Lowering...

Hypertension

The principal scientific objective of the trial is to identify the factors that are associated with differential blood pressure responses between drugs. This may allow investigators to produce new hypotheses on the pathophysiology of hypertension and on the mechanisms of drug action. These factors can be of different types: Environmental factors (sodium or alcohol intake); Morphological (height, weight, body mass index, body surface area); Initial blood pressure; Electrocardiogram (ECG) parameters of left ventricular hypertrophy; Biological parameters as the activity level of the renin angiotensin aldosterone system; Genetic polymorphisms.

Completed4 enrollment criteria

Efficacy and Safety of Oral Bosentan in Pulmonary Arterial Hypertension Class II

Pulmonary Hypertension

The present trial investigates a possible use of oral bosentan, which is currently approved for the treatment of symptoms of pulmonary arterial hypertension (PAH) Class III and IV, to patients suffering from PAH Class II.

Completed8 enrollment criteria

Telmisartan vs. Valsartan in Patients With Mild to Moderate Hypertension Following a Missed Dose...

Hypertension

The primary objectives are to demonstrate that MICARDIS® (telmisartan) is statistically superior to Diovan® (valsartan) in reducing diastolic blood pressure (DBP) following a missed dose at the end of a 6 to 8-week treatment period as measured by the 24-hour ABPM mean and to demonstrate that MICARDIS® is statistically superior to Diovan® in reducing DBP during the last 6-hours of the 24-hour dosing interval as measured by ABPM following a dose of active study medication at the end of a 6 to 8-week treatment period.

Completed32 enrollment criteria
1...317318319...587

Need Help? Contact our team!


We'll reach out to this number within 24 hrs